Loading…
Conexeu Sciences Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in CNXU.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| LUCDLucid Diagnostics Inc. | $0.99 | — | 17.4x | — | -556.27% | $189.31M |
| VRXAVeraxa Biotech AG - Post de-SPAC | $1.35 | — | 0.5x | — | -65.29% | $190.9M |
| AIRSAirsculpt Technologies, Inc. | $2.60 | — | 1.8x | — | -11.98% | $187.45M |
| ORGOOrganogenesis Holdings Inc. |
Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair. The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (ECM) scaffold platform for use in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring such as face, breast, and butt volume restoration. Its CXU collagen gel is an investigational product targeting therapeutic and aesthetic indications, supporting tissue regeneration and aiming to minimize inflammation or fibrosis. The company's solutions are supported by preclinical and peer-reviewed data and are positioned as alternatives to conventional fillers or implants, with products currently investigational and pending regulatory clearance for certain applications. The company serves clients in the beauty, aesthetics, regenerative medicine, and medical sectors, including clinicians and professionals involved in facial rejuvenation, body contouring, wound care, and tissue repair. The company was founded in 2022 and is based in Reno, Nevada.
Company description provided by Yahoo Finance.
| $1.45 |
| — |
| 1.3x |
| — |
| -25.92% |
| $186.58M |
| MSLESatellos Bioscience Inc. | $8.66 | — | 3.0x | — | -70.45% | $183.73M |
| ANTXAN2 Therapeutics, Inc. | $4.83 | — | 2.3x | — | -50.12% | $182.27M |